tirzepatide ban update WADA just added (mounjaro) to the 2026 Monitoring Program The FDA is proposing a

Evidence on PsA remains limited, with only one open-label clinical study available to date

Phentermine is not a GLP-1 drug

GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study

The data stack that accompanied this policy revision was exceptional by any measure: Phase 3 results for five separate drug programs the oral GLP-1 orforglipron, the triple-hormone-receptor agonist retatrutide, Novo Nordisk's CagriSema combination, the dual agonist survodutide, and the PCSK9 inhibitor evolocumab were presented at the meeting and in several cases simultaneously published in peer-reviewed journals

It is also known as liquid paraffin